Votre Partenaire en Modélisation & Simulation Pharmacocinétique !

PhinC met en place la meilleure stratégie de Modélisation & Simulation pour orienter les étapes clefs de votre développement et optimiser ses coûts.
Les services PhinC
Nos actualités

Ils nous font confiance

Pascal Benderitter
Pascal Benderitter
Senior Program Director NCX - Oncodesign Precision Medicine
In the frame of the preclinical development of our main asset, we have been looking after experts in the modeling of pharmacokinetics. Working with PhinC, a member of the AFFSSI, has only seemed natural in regards with their recognized expertise and by a common vision of long-term collaboration. Their work on a PBPK model was a clear added value in the regulatory filing and contributed to the approval of the clinical trial application early 2023. We are happy to count them among the key players in the ongoing clinical study on ODS-101.
Sakina Sayah-Jeanne
Sakina Sayah-Jeanne
Senior Director, Translational R&D - Da Volterra
PhinC has been accompanying Da Volterra for several years on PBPK Modelling activities. Our collaboration, based on mutual trust, has already been very fruitful and has allowed Da Volterra to gain precious knowledge on its product under development. Da Volterra enjoys working with PhinC and will continue to do so in the years to come, leaning from its expertise.
John DiBella
John DiBella
President, Lancaster Division - Simulations Plus, Inc. (NASDAQ: SLP)
Simulations Plus has formed a strong relationship with PhinC as we work together to drive increased adoption of physiologically-based pharmacokinetic (PBPK) modeling to support pharmaceutical research and development. Their talented team of scientists have become proficient users of our GastroPlus™ software platform, and we are confident that the services they provide to clients are valuable and greatly impact R&D productivity.
Olivier Lacombe
Olivier Lacombe
Head of Pharmacokinetics - Inventiva
Inventiva and PhinC have been collaborating for several years on popPK and PBPK modeling activities. The decision to work with PhinC was based on the team expertise in pharmacokinetics and modeling within drug development, and their aptitude to react and to collaborate within a biotech context. Moreover their approach is based on the client listening and project understanding in order to propose the most adequate proposal to the request. Our relationship is very pleasant, efficient and fruitful for both the scientific and project outputs.
Club Phase 1
GMP - Groupe de Métabolisme et Pharmacocinétique
EUFEMED
AFSSI
MabDesign
Oncodesign services
Paris Saclay
France Biotech
Paris Region Business Club
Medicen
French Tech Paris-Saclay
Genopole